Cancer immunotherapy has emerged as one of the most exciting directions in cancer treatment. But the approach only works in a fraction of patients and can cause nasty side effects. Now scientists report the development of the first dual-cell targeting immunotherapy nanoparticle that slows tumor growth in mice with different cancers. In their study, up to half the mice in one cancer group went into full remission after the treatment.